Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 85.24

+0.5%

Feb 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (3300)	8/5/2015 12:59:40 PM
From: Miljenko Zuanic	Read Replies (1) of 3722

FOVISTA first P3 read out (IF they reported each trial separately) is ~+9 months away (~mid 2016), so any move, right now, is premature. REGN competing drug ( from ophr pr: ...subject to delays related to the summer season and/or the initiation of competing trials.....) will have P2b read out at the some time, so "intriguing" double binary event. Regards the Zimura in IPCV, it is only 5 pts trial, so what to take out of that???? From pr: and the initiation of our Phase 2/3 dry AMD program with Zimura....FROM WHERE this come in????? Move Dr. David T. Shima from Roche to OPHT, ...???? maybe he/she (?) want to be "pioneer" in treatment for dry AMD/fibrosis? PS: Hope your stoop trigger was good one.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next